AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$ARTV

Banerjee Subhashis sold $12K of ARTV

Banerjee Subhashis (Chief Medical Officer) sold 1,100 shares of Artiva Biotherapeutics, Inc. (ARTV) at $11.16 on 2026-09-03.

Original reporting
SEC EDGAR · Banerjee Subhashis
Published Sep 4, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
medium confidence
Mentioned
$ARTV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

The transaction is a routine sale with limited market impact.

02

Market read

Minor insider sale; unlikely to affect price or sector sentiment.

03

What to watch

The insider still holds 140,947 shares, indicating confidence despite the sale.

Relevance 3/10Novelty 2/10Timing: post filing 2026-09-04

Background

Form 4 filing from SEC EDGAR reporting an insider transaction.

Company-level read

Ticker impact

$ARTVNeutralMedium confidence
Context

Chief Medical Officer Banerjee Subhashis sold 1,100 shares for $12,271 on 2026-09-03 via an open‑market transaction.

Expected impact

minimal downward pressure, likely negligible

Evidence & confidence

The sale size ($12k) is tiny relative to market cap and insider holdings; no indication of distress.

Market effects

Sector

None; biotech sector not affected by a micro insider sale.

Regional

None; only a US‑listed micro‑cap is involved.

Global

None

Counterpoint

What could challenge this read

Even small insider sales can signal concerns; monitor subsequent filings for pattern.

Key entities

  • Company
    Artiva Biotherapeutics, Inc.

    US‑listed biotech (NASDAQ: ARTV).

  • Executive
    Banerjee Subhashis

    Chief Medical Officer of Artiva Biotherapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ARTV insider trading history →

Related articles

OCT 27
$ARTVLow

Artiva Biotherapeutics, Inc. (ARTV): Results of Operations and Financial Condition

Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK ® • Company halting further development of AlloNK ® (AB-101), including the planned phase 3 pivotal trial • Updated deep B cell depletion and clinical response data is consistent

SEC EDGAR 8-K2 min
OCT 27
$ARTVHighAI 8/10

Why is Artiva Biotherapeutics stock collapsing today?

Artiva Biotherapeutics' stock fell 30% after halting AlloNK (AB-101) development due to safety events and poor clinical data. The company plans to cut 94% of its workforce and explore strategic alternatives, including liquidation. CEO and COO sold shares before the announcement. Artiva had $319.1M in cash as of September 30. The stock traded at $4.31, far below its 52-week high of $14.53.

investing.com2 min